Published in Leuk Lymphoma on May 01, 2004
Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science (2001) 4.61
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 2.50
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia (2006) 2.38
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem (1995) 1.86
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum Gene Ther (1995) 1.52
Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther (2001) 1.47
Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.42
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer (2010) 1.42
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood (2001) 1.41
[Vaccination against rabies: how and when?]. Dtsch Med Wochenschr (2012) 1.41
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res (1996) 1.36
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem (1994) 1.33
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood (2000) 1.29
Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother (2010) 1.28
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia (2007) 1.25
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.24
Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood (1992) 1.21
Receptor targeting of adeno-associated virus vectors. Gene Ther (2003) 1.20
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia (2009) 1.16
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia (2010) 1.15
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia (2012) 1.14
Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia (2008) 1.13
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia (2012) 1.13
Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther (2003) 1.12
The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem (1997) 1.10
ATP-binding properties of human Hsp90. J Biol Chem (1997) 1.06
Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol (1999) 1.02
Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines. Leukemia (1997) 0.98
Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis (2008) 0.97
Determinants and implications of cancer patients' psychosocial needs. Support Care Cancer (2009) 0.97
Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology (Oxford) (2008) 0.95
Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill (2012) 0.92
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev (2007) 0.92
Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant (2008) 0.91
Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia (2011) 0.90
Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia (2011) 0.90
The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res (2000) 0.89
Current status of immunotherapy in B cell malignancies. Curr Drug Targets (2006) 0.89
Progressive multifocal leucoencephalopathy in a patient with sarcoidosis--successful treatment with cidofovir and mirtazapine. Rheumatology (Oxford) (2007) 0.89
Annual variation in semen characteristics and plasma hormone levels in men undergoing vasectomy. Fertil Steril (1988) 0.89
Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases. Mol Cell Biol (2001) 0.88
Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther (2007) 0.87
The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia (2003) 0.87
Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother (2011) 0.87
Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med (Berl) (1999) 0.87
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia (2013) 0.86
Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Proc Natl Acad Sci U S A (1999) 0.85
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia (2012) 0.85
Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases. Oncogene (2007) 0.85
Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol (1995) 0.85
CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line. Cancer Res (1995) 0.83
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol (2000) 0.83
Purification and characterization of prokaryotic and eukaryotic Hsp90. Methods Enzymol (1998) 0.83
Interleukin-6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP-1. Eur J Immunol (1996) 0.83
Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford) (2008) 0.82
Gabor-like image filtering using a neural microcircuit. IEEE Trans Neural Netw (2007) 0.82
Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the "real-life setting" proves the concept. Eur J Med Res (2011) 0.82
Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther (2011) 0.81
Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients. Infection (2010) 0.81
The German competence network 'Acute and chronic leukemias'. Leukemia (2004) 0.81
Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 0.81
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer (2013) 0.80
[Multimodality therapy of colorectal cancer]. Internist (Berl) (2010) 0.80
Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Ther (1999) 0.79
Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia. Leukemia (2011) 0.79
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol (2012) 0.79
[Elderly patients in clinical trials: new fitness-adapted concepts]. Internist (Berl) (2007) 0.79
Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. Leukemia (2010) 0.79
Dipeptidyl peptidase IV (DPP IV, CD26) in patients with mental eating disorders. Adv Exp Med Biol (2000) 0.79
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals. Eur J Med Res (2010) 0.79
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 0.78
Necrotizing pneumonia caused by Panton-Valentine leucocidin-producing Staphylococcus aureus originating from a Bartholin's abscess. Infect Dis Obstet Gynecol (2008) 0.78
A novel directed evolution method to enhance cell-type specificity of adeno-associated virus vectors. Comb Chem High Throughput Screen (2010) 0.78
Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma (1997) 0.78
Novel and emerging drugs for chronic lymphocytic leukemia. Curr Cancer Drug Targets (2012) 0.78
Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination. Gene Ther (2006) 0.78
Circadian variation of the phagocytic activity of polymorphonuclear leukocytes and of various other parameters in 13 healthy male adults. Chronobiol Int (1992) 0.78
Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics. Int J Cancer (1994) 0.78
[Tyrosine kinase inhibitors in oncology]. Internist (Berl) (2011) 0.77
Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (1998) 0.77
Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.77
Effects of a bacterial extract on local immunity of the lung in patients with chronic bronchitis. Lung (1990) 0.77
Association of high plasma antioxidant capacity with new lesion formation in carotid atherosclerosis: a prospective study. Eur J Clin Invest (1998) 0.77
Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. Hum Gene Ther (1998) 0.77
Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Ther (2004) 0.77
[Hematology 2008]. Dtsch Med Wochenschr (2008) 0.77
Reconstitution of the cellular immune response after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin's lymphoma. Br J Haematol (2000) 0.77
Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression. Eur J Clin Invest (1997) 0.77